CARs Moving Forward: The Development of CAR T-Cell Therapy in the Earlier Treatment Course of Hematologic Malignancies

IF 5 3区医学 Q1 HEMATOLOGY

Seminars in hematology Pub Date : 2024-10-01 DOI:10.1053/j.seminhematol.2024.08.005

Omar Castaneda Puglianini , Julio C. Chavez

引用次数: 0

Abstract

Chimeric antigen receptor T-cell (CAR-T) has revolutionized the treatment of hematologic malignancies. There are several approvals in lymphomas, leukemias and myeloma. Randomized clinical trials have shown that CAR-T cell therapy improves survival over standard of care in diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM), changing dramatically the current treatment paradigm. Current efforts are directed in improving outcomes in the frontline setting and confirmatory randomized trials are ongoing.

查看原文本刊更多论文

CARs 勇往直前：CAR T 细胞疗法在血液恶性肿瘤早期治疗过程中的发展。

嵌合抗原受体 T 细胞（CAR-T）彻底改变了血液系统恶性肿瘤的治疗。目前已有数种淋巴瘤、白血病和骨髓瘤获得批准。随机临床试验表明，与标准疗法相比，CAR-T 细胞疗法提高了弥漫大 B 细胞淋巴瘤（DLBCL）和多发性骨髓瘤（MM）的生存率，极大地改变了目前的治疗模式。目前的努力方向是改善一线治疗的疗效，确证性随机试验正在进行中。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Seminars in hematology 医学-血液学

CiteScore

6.20

自引率

2.80%

发文量

审稿时长

35 days

期刊介绍： Seminars in Hematology aims to present subjects of current importance in clinical hematology, including related areas of oncology, hematopathology, and blood banking. The journal''s unique issue structure allows for a multi-faceted overview of a single topic via a curated selection of review articles, while also offering a variety of articles that present dynamic and front-line material immediately influencing the field. Seminars in Hematology is devoted to making the important and current work accessible, comprehensible, and valuable to the practicing physician, young investigator, clinical practitioners, and internists/paediatricians with strong interests in blood diseases. Seminars in Hematology publishes original research, reviews, short communications and mini- reviews.